INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Liver Transplant Recipients have received liver    │ Liver Transplant Recipients have received liver    │     100 │
│ transplantations for at least 6+1 months prior to  │ transplantations for at least 6+1 months prior to  │         │
│ enrollment                                         │ enrollment                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver Transplant Recipients have no acute          │ Liver Transplant Recipients have no acute          │     100 │
│ rejection episodes within 3 months prior to the    │ rejection episodes within 3 months prior to the    │         │
│ enrollment and are clinically stable               │ enrollment and are clinically stable               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver Transplant Recipients have been treated with │ Liver Transplant Recipients have been treated with │     100 │
│ twice-daily regimen of tacrolimus(TAC) plus        │ twice-daily regimen of tacrolimus(TAC) plus        │         │
│ everolimus(EVR) and TAC and EVR trough levels have │ everolimus(EVR) and TAC and EVR trough levels have │         │
│ stayed within targeted ranges for at least 6 weeks │ stayed within targeted ranges for at least 6 weeks │         │
│ prior to enrollment                                │ prior to enrollment                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Provide written informed consent prior to          │ Provide written informed consent prior to          │     100 │
│ inclusion                                          │ inclusion                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver transplant recipients who are 18-65 years of │ Liver transplant recipients who are 18-65 years of │     100 │
│ age of a primary liver transplant                  │ age of a primary liver transplant                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of malignancy of any organ system (other   │ History of malignancy of any organ system (other   │     100 │
│ than localized basal cell carcinoma of the skin),  │ than localized basal cell carcinoma of the skin),  │         │
│ treated or untreated, within the past 5 years,     │ treated or untreated, within the past 5 years,     │         │
│ regardless of whether there is evidence of local   │ regardless of whether there is evidence of local   │         │
│ recurrence or metastases                           │ recurrence or metastases                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Existence of any surgical, medical or mental       │ Existence of any surgical, medical or mental       │     100 │
│ conditions, other than the current                 │ conditions, other than the current                 │         │
│ transplantation, which, in the opinion of the      │ transplantation, which, in the opinion of the      │         │
│ investigator, might interfere with the objectives  │ investigator, might interfere with the objectives  │         │
│ of the study                                       │ of the study                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing (lactating) women              │ Pregnant or nursing (lactating) women              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are recipients of multiple solid      │ Abbreviated MDRD eGFR = 30 mL/min/1.73m2. Patients │      90 │
│ organ or islet cell tissue transplants, or have    │ who are recipients of multiple solid organ or      │         │
│ previously received an organ or tissue transplant. │ islet cell tissue transplants, or have previously  │         │
│ Patients who have a combined liver-kidney          │ received an organ or tissue transplant. Patients   │         │
│ transplant                                         │ who have a combined liver-kidney transplant        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Allograft functioning at an acceptable level as    │ Allograft functioning at an acceptable level as    │      99 │
│ defined by the AST, ALT, Total Bilirubin levels ≤3 │ defined by the AST, ALT, Total Bilirubin levels =3 │         │
│ times ULN prior to enrollment                      │ times ULN prior to enrollment                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Abbreviated MDRD eGFR ≥ 30 mL/min/1.73m2. Key     │ Abbreviated MDRD eGFR = 30 mL/min/1.73m2. Patients │      30 │
│                                                   │ who are recipients of multiple solid organ or      │         │
│                                                   │ islet cell tissue transplants, or have previously  │         │
│                                                   │ received an organ or tissue transplant. Patients   │         │
│                                                   │ who have a combined liver-kidney transplant        │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                 │ Provide written informed consent prior to          │      33 │
│                                                   │ inclusion                                          │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 65 Years                 │ Liver transplant recipients who are 18-65 years of │      34 │
│                                                   │ age of a primary liver transplant                  │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients fulfilling any of the following criteria │ Liver Transplant Recipients have no acute          │      41 │
│ are not eligible for inclusion in this study      │ rejection episodes within 3 months prior to the    │         │
│                                                   │ enrollment and are clinically stable               │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stable liver transplant recipients are eligible   │ Liver Transplant Recipients have received liver    │      51 │
│ for inclusion in this study and have to fulfill   │ transplantations for at least 6+1 months prior to  │         │
│ all of the following criteria                     │ enrollment                                         │         │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 90
Average Levenshtein Ratio of individual lines: 78.53333333333333
OverAll Ratio: 84.26666666666667
